is a technology-driven biopharmaceutical company that provides formulation and drug delivery solutions to small and large molecules. We focus on the development of innovative and generic drug products with high technical barriers. In addition to the development of most challenging first-to-file generics, we provide CRO services, including formulation, analytical method development, and toxicology evaluation services, for pharma, biotech, and medical research institutions all over the world. Our innovative formulation and drug delivery platforms provide our clients with accelerated molecules to medicines and speedy product development, which enable their products to be best in class and first in market. Learn more at https://candoopharmatech.com. We have an incredible team of bright, passionate, and committed individuals who are dedicated to our mission. Our mission is to develop clinically differentiated, effective, and affordable medicines to address unmet medical needs, enhance therapeutic efficacy, and improve patients’ lives with our innovative drug delivery technologies. We’d love to hear how you could contribute to the team! Research at Candoo is innovation-oriented as we focus on the development of pharmaceutical products which are novel, high technical barrier, and hard to make. We have extensive experience and proven track record on NCE, 505 b(2), and complex generic product development for the oral delivery of small and large molecules. Our expertise includes preformulation, formulation and analytical development, solubility and permeability enhancement, bioavailability and bioequivalence, technology transfer, scale up, nonclinical toxicology evaluation, and regulatory submission. Candoo is incorporated by McCarthy Tetrault LLP and is a Canadian subsidiary of Crystal Pharmatech Co Ltd. As a member of Ontario Research Innovation and Commercialization Center, Candoo has a state-of-the-art facility in Mississauga, Ontario.
